Dr. Bruce Levine is the Barbara and Edward Netter Professor in Cancer Gene Therapy in the Department of Pathology and Laboratory Medicine at the University of Pennsylvania. He is the Director of the Clinical Cell and Vaccine Production Facility (CVPF) at the Abramson Cancer Center and Perelman School of Medicine. He is an alumnus of the University of Pennsylvania and received his Ph.D. in Immunology and Infectious Diseases from the Johns Hopkins University. The CVPF enables the translation and development of novel cell and gene therapies through validation, manufacture, and testing in single center and multi-center clinical trials in hematologic malignancies, solid tumors, HIV infection, and genetic disease. Twenty clean rooms and associated Quality Control laboratories staffed by 60 clinical laboratory scientists and regulatory professionals support the mission. Since inception, Dr. Levine and the CVPF have supported >30 FDA IND Applications. Several CVPF trials have been first-in-human trials, including the first use of a lentiviral vector, the first infusions of zinc finger nuclease genome-modified cells, and the first use of lentivirally-modified cells to treat cancer. Dr. Levine has overseen the production, testing and release of 2300 cellular products administered to >850 patients in clinical trials since 1996. Through these technologies, personalized and enhanced immunity has been engineered. T lymphocytes from HIV+ subjects have been rendered resistant to HIV infection and reinfused. T lymphocytes from cancer patients have been redirected with chimeric antigen receptors to hunt and destroy their malignancies, an investigational therapy that recently received Breakthrough Designation from the FDA and is currently in commercial development. Dr. Levine is co-inventor on 16 issued US patents and co-author of >120 publications with a Scopus citation h-index of 52.